
Charles Darwin University

Hepatitis D is rare or non-existent in hepatitis B virus-infected Indigenous Australians in the Northern Territory

Davies, Jane; Tong, Steven; Davis, Joshua

Published in:
Australian and New Zealand Journal of Public Health

DOI:
[10.1111/1753-6405.12040](https://doi.org/10.1111/1753-6405.12040)

Published: 01/01/2013

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):
Davies, J., Tong, S., & Davis, J. (2013). Hepatitis D is rare or non-existent in hepatitis B virus-infected Indigenous Australians in the Northern Territory. *Australian and New Zealand Journal of Public Health*, 37(2), 188-189. <https://doi.org/10.1111/1753-6405.12040>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Hepatitis D is rare or non-existent in hepatitis B virus-infected Indigenous Australians in the Northern Territory

Jane Davies

Menzies School of Health Research at Charles Darwin University, Darwin, NT; Royal Darwin Hospital, Infectious Diseases Department, Darwin, NT

Steven Y.C. Tong

Menzies School of Health Research at Charles Darwin University, Darwin, NT

Joshua S. Davis

Menzies School of Health Research at Charles Darwin University, Darwin, NT; Royal Darwin Hospital, Infectious Diseases Department, Darwin, NT

Hepatitis D virus (HDV), the causative agent of delta hepatitis or hepatitis D, infects 18 million people worldwide with significant regional variation in prevalence.¹ As it requires an individual to be co-infected with hepatitis B virus (HBV) to maintain its replication, its distribution tends to mirror that of chronic HBV infection globally. Although there has been a decline in HDV infection rates over the past few decades in Europe, it remains a significant problem in parts of sub-Saharan Africa, South America and the Asia-Pacific region, as well as in high risk populations such as injecting drug users (IDU) and men who have sex with men (MSM).

In Australia, Hepatitis D is a notifiable disease. There were 34 cases reported nationally in 2010 and 36 in 2011. There has only been one case notified from the Northern Territory (NT) in the past 10 years (this was in a non-Indigenous IDU).² Data from the 1980s looking at hepatitis B positive IDUs in Melbourne and MSM in Sydney reported HDV infection rates of 19-20% and 4.4% respectively.^{3,4} Current Gastroenterological Society of Australia

Table 1: Patient demographics and HDV status (n=55).

Median age	36.4 years (IQR 28-46)
Male	28 (51%)
Indigenous status	55 (100%) Indigenous Australian
Home region ^a	East Arnhem Land 16 (29.1%) West Arnhem Land 9 (16.4%) Tiwi Islands 6 (10.9%) Darwin urban 1 (1.8%) Katherine region 11 (20.0%) Daly River region 12 (21.8%)
eAg status	Positive 30 (55%) Negative 25 (45%)
eAb status	Positive 25 (45%) Negative 30 (55%)
HDV antigen and antibody	Negative 55 (100%)

a Main residence during first five years of life.

Chronic Hepatitis B guidelines⁵ recommend baseline testing for HDV in HBV-infected individuals from higher risk countries – specifically the *Pacific Islands, Mediterranean, parts of South America and Africa*.

Hepatitis B is endemic in NT Indigenous communities and there is uncertainty as to whether they constitute a high-risk group who would warrant HDV testing at the time of initial hepatitis B diagnosis. We sought to address this question by prospectively recruiting a cohort of hepatitis B positive Indigenous individuals.

Between June 2010 and June 2012, following approval from the local human research ethics committee, and written informed consent, we tested 55 hepatitis B positive Indigenous individuals from across the Top End of the NT for HDV antibody and antigen. We found no positive results (Table 1). A subset of 13 samples was further tested for HDV RNA and all were not detected. Hence we estimate the prevalence of HDV in HBV-infected Indigenous people of the NT to be 0% (one-sided 95% confidence interval 0%-6.5%).

Based on these prospectively collected data, HDV infection is either rare or does not exist in NT Indigenous communities and we can therefore recommend that screening is not routinely required.

Acknowledgements

We thank Drs Scott Bowden and Stephen Locarnini for running the relevant laboratory assays at the Victorian Infectious Diseases Reference Lab and Dr Krispin Hajkovicz for help with patient recruitment.

References

1. Abbas Z. Hepatitis D: Scenario in the Asia-Pacific region. *World J Gastroenterol*. 2010;16(5):554-62.
2. Department of Health and Ageing. *National Notifiable Diseases Surveillance System Report Type 4 – Hepatitis D by Year and State* [Internet]. Canberra (AUST): Commonwealth of Australia; 2012 [cited 2013 Mar 11]. Available from: <http://www.health.gov.au/internet/main/publishing.nsf/content/cda-surveil-ndss-ndssintro.htm>
3. Dimitrakakis M. Epidemiology of hepatitis D virus (delta) infection in Melbourne over a 15-year period. *Med J Aust*. 1986;145(3-4):128-30.
4. Bodsworth NJ, Donovan B, Gold J, Cossart YE. Hepatitis delta virus in homosexual men in Sydney. *Genitourin Med*. 1989;65(4):235-8.
5. Digestive Health Foundation. *Australian and New Zealand Chronic Hepatitis B (CHB) Recommendations*. 2nd ed. Melbourne (AUST): Gastroenterological Society of Australia; 2009/10. http://www.gesa.org.au/files/editor_upload/File/Professional/CHB.pdf

Correspondence to: Dr Joshua S. Davis, Menzies School of Health Research – Global and Tropical Health Division, Rocklands Drive, Tiwi, Darwin, Northern Territory 0811; e-mail: Joshua.Davis@menzies.edu.au